Ab#1582 @RheumNow #ACR23 RA-ILD outcomes of TNFi v non-TNF b/tsDMARD VA Data, propens match emulation study No incr risk of death in TNFi vs non-TNFi But are TNF safe? - Don't support systematic avoidance. But are there specific pops - unsure. Don't answer if efficacy in RA-ILD https://t.co/AApEjZs4DM

Important plenary session, RA-ILD outcomes in VA cohort study No difference in death/hospitalization for TNF vs non-TNF treated patients. Jives w/my priors; I do NOT avoid TNF in RA-ILD Encouraging if you (like me) prefer RA-active tx for RA-ILD 😉😆 @RheumNow #ACR23 #ACRBest https://t.co/TIDzMLOfs4

Non TNFi b/tsDMARDs vs TNFi in RA-ILD. New-User, Propensity Score Matched Study. 454 patients. No difference! resp-related hospitalisation aHR 1.22 [0.92, 1.60] No difference mortality. Abstr#1582 #ACR23 #ACRbest @RheumNow https://t.co/HzzVo9dJHi https://t.co/mZuHq4GShU

The SMART study by Dhir et al: once-weekly, oral split-dose MTX (10mg/15mg) in RA pts had⬆️efficacy & ⬇️need for addtl DMARDs vs. once-weekly, single-dose MTX Reassuring. . . . In my practice, pts tolerate MTX split dosing better esp w/⬆️doses #ACR23 ABST1583 @RheumNow https://t.co/F8p2aKmmH4

Long term follow up T2T in RA 12 yrs BeST & 20yrs IMPROVED studies 50% recalled 68% remission 91% LDA HAQ 0.5 These are GOOD outcomes Especially considering setup before we had several MoAs What’s lacking: current ttmt & number of bioD, ctrl group @RheumNow ABST1273 #ACR23 https://t.co/9KcsHLupJc

RA-ILD is an heterogeneous condition Different risk factors identified dep/ on radiographic pattern RA-UIP: -male sex OR 2.7 -ACPA+ OR 2.2 -male + ACPA + smoking OR 13 RA-NSIP: -RF+ OR 3.2 Likely to support different pathological mechanisms @RheumNow #ACR23 ABST1269 https://t.co/rC2F9YAceQ

Never forget the physical toll that RA has taken on our patients. RA pts in BC🇨🇦, dx 1996-2008 (n=13367) Fraility score 5y post-dx: twice as likely to be frail vs matched controls I would love to see those dx 2008-2018 Have biologics moved the needle? #ACR23 ABST1275 @RheumNow https://t.co/gMXo5Pp1qA

RA peripheral blood mononuclear cells display IFN-gamma signature Driven by 2 cell subsets: T cells & macrophages IFNg driven transcription factors Increased only in ACPA+ RA Differential biology could inform ACPA stratified therapy ABST1271 @RheumNow #ACR23 https://t.co/EN2noKGupK

To remind us. Glory be! GLORIA a #RCT in elderly active #RA: MTX+10 mg daily #prednisolone which was better than MTX alone. But more infections and no comparison of inexpensive Rx such as adding #HCQ. Still debated as to benefit vs risk of this strategy @RheumNow #ACR23 @ACRheum https://t.co/slOmESbIOW

Have we forgotten our physical rehab roots in RA? RA with severe functional disability 1y of personalised exercise program vs routine care n=215, Leiden broad functional gains as expected Remember: the meds are critical, but can only take you so far. #ACR23 ABST1335 @RheumNow https://t.co/FszhGAv7ln